Kyntheum, also known by its generic name brodalumab, is a prescription medication used in the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It belongs to a class of drugs known as interleukin inhibitors, specifically targeting the interleukin-17 (IL-17) receptor, a key player in the inflammatory process associated with psoriasis. By blocking the action of IL-17, Kyntheum helps to reduce the inflammation, scaling, and thickness of psoriatic plaques, leading to an improvement in symptoms and skin appearance. It is administered through subcutaneous injection and is typically recommended for patients who have not responded adequately to other systemic therapies. As with any medication, it is important to use Kyntheum under the guidance of a healthcare professional, as it can have potential side effects and may not be suitable for everyone.